RxDoctor Payments Data

Devendra Vora, MD

Cardiovascular Disease · Tacoma, WANPI 1417931627

Payments from drug & device makers

$529in general payments, 2019–2025

Across 21 payments — averaging $25.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$113
  • Johnson & Johnson$97
  • Boston Scientific$66
  • Kestra Medical Technology Services, Inc.$57
  • AstraZeneca$45
  • Novartis$37
  • plus $115 from 5 others

What the payments were for

  • Food & beverage$48391%
  • Education$469%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$529 in reported general payments places this provider in the 40th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$432,281
Medicare patients
968
Services billed
3,096

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban509$595,478
XareltoRivaroxaban204$233,084
EntrestoSacubitril/Valsartan70$64,912
Repatha SureclickEvolocumab23$34,751
Metoprolol Succinate1,143$18,231
Praluent PenAlirocumab24$15,430
BrilintaTicagrelor16$13,124
LivaloPitavastatin Calcium18$10,126
Ranolazine ErRanolazine122$9,949
JardianceEmpagliflozin14$9,392
Rosuvastatin Calcium535$8,486
Atorvastatin Calcium805$7,575
Carvedilol714$5,714
Ezetimibe292$5,619
Isosorbide Mononitrate ErIsosorbide Mononitrate499$5,084

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$97$233,084204 claims
NovartisEntresto$37$64,91270 claims
AstraZenecaBrilinta$45$13,12416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →